Division of Cardiovascular Medicine, Texas Tech University Health Sciences Center, El Paso, TX, USA.
Curr Cardiol Rep. 2020 Jan 21;22(2):7. doi: 10.1007/s11886-020-1259-9.
Our review discusses the management of post percutaneous coronary intervention angina (PPCIA) which negatively impacts 20-40% of patients and imposes a high burden on the healthcare system.
Mechanisms of PPCIA include microvascular dysfunction, distal coronary vasospasm or disease, microembolization, myocardial bridge, coronary artery disease (CAD) progression, and rarely stent thrombosis or in-stent restenosis. Nitrates, beta blockers (BB), calcium channel blockers, and ranolazine are the common medical management options. Only BB showed 1-year mortality benefit following myocardial infarction. Stress echocardiography and cardiac magnetic resonance are the best to detect CAD vs. microvascular dysfunction. Invasively, vasoprovocative testing and fractional flow reserve provide useful prognostic information. If the ischemia burden is ≤10%, conservative management should be considered based upon the individual patient scenario. The optimal management of PPCIA remains unclear and further research is necessary. Multiple treatment options exist, which should be implemented in an individualized fashion.
本综述讨论了经皮冠状动脉介入治疗后心绞痛(PPCIA)的管理,其影响 20-40%的患者,并给医疗系统带来了沉重负担。
PPCIA 的机制包括微血管功能障碍、远端冠状动脉痉挛或疾病、微栓塞、心肌桥、冠状动脉疾病(CAD)进展,以及罕见的支架血栓形成或支架内再狭窄。硝酸盐、β受体阻滞剂(BB)、钙通道阻滞剂和雷诺嗪是常见的药物治疗选择。只有 BB 在心肌梗死后显示出 1 年的死亡率获益。超声心动图和心脏磁共振是检测 CAD 与微血管功能障碍的最佳方法。在有创性检查中,血管扩张性药物激发试验和血流储备分数提供了有用的预后信息。如果缺血负担≤10%,根据患者具体情况应考虑保守治疗。PPCIA 的最佳治疗方法仍不清楚,需要进一步研究。有多种治疗选择,应根据个体患者情况进行个体化实施。